Sanofi S.A. Stock
€86.43
Your prediction
Sanofi S.A. Stock
Pros and Cons of Sanofi S.A. in the next few years
Pros
Cons
Performance of Sanofi S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sanofi S.A. | 1.090% | -1.498% | -2.764% | -15.111% | -4.735% | 0.164% | 16.184% |
| Ipsen S.A. | 1.320% | -3.724% | 0.474% | 0.379% | -1.119% | 37.164% | -10.017% |
| Elanco Animal Health Inc. | -1.360% | -7.271% | -12.163% | 50.047% | -5.666% | -49.025% | - |
| Pfizer Inc. | 0.190% | -2.851% | -6.654% | -35.541% | -8.621% | -25.863% | -28.239% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance at the financial statements of Snof, a pharmaceutical company, it appears that the company has experienced growth in key financial metrics such as total assets, total revenue, and net income. Over the recent years, the company has demonstrated a consistent increase in these indicators, reflecting positively on its financial health.
Growth in Total Assets: The total assets of Snof have grown consistently over the past three years, from €114.53 billion in 2020 to €120.24 billion in 2021, and eventually to €124.58 billion in 2022. This growth signifies that the company is expanding and successfully acquiring more resources to fuel its operations.
Increasing Revenue: Snof's total revenue has been on an upward trajectory, as evidenced by its growth from €37.37 billion in 2020 to €39.18 billion in 2021 and €45.39 billion in 2022. This demonstrates the company's ability to generate higher sales, which is essential for sustaining its growth trajectory.
